Free tool
FAERS Monitor: Xdemvy
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217603 or its brand name (Xdemvy, Lotilaner). Reports on generic versions are filed under their own applications.
Reports
3,918
Serious
320
8% of reports
Hospitalization
79
Death reported
39
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- eye irritation491
- off label use417
- ocular hyperaemia322
- product use issue315
- condition aggravated280
- eye pain277
- vision blurred267
- therapy interrupted253
- wrong technique in product usage process252
- eye pruritus214
- drug ineffective199
- product prescribing issue167
- instillation site irritation149
- lacrimation increased144
- eye swelling130
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 22 |
| 2024 | 776 |
| 2025 | 1,254 |
| 2026 | 1,863 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,241 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| instillation site irritationSignal | 149 | 773.5 | 653.3 | 99,814 |
| eye irritationSignal | 491 | 46.2 | 42.5 | 21,532 |
| product prescribing issueSignal | 167 | 41.5 | 35.7 | 6,510 |
| ocular hyperaemiaSignal | 322 | 36.7 | 33.0 | 11,085 |
| eye pruritusSignal | 214 | 34.4 | 30.2 | 6,874 |
| eye painSignal | 277 | 26.5 | 23.6 | 6,751 |
| lacrimation increasedSignal | 144 | 25.7 | 21.9 | 3,383 |
| therapy interruptedSignal | 253 | 19.1 | 16.9 | 4,313 |
| eye swellingSignal | 130 | 18.8 | 15.9 | 2,172 |
| vision blurredSignal | 267 | 10.5 | 9.3 | 2,285 |
| product use issueSignal | 315 | 9.0 | 8.1 | 2,252 |
| wrong technique in product usage processSignal | 252 | 6.7 | 5.9 | 1,222 |
| condition aggravatedSignal | 280 | 4.9 | 4.4 | 890 |
| off label useSignal | 417 | 2.6 | 2.3 | 411 |
| drug ineffective | 199 | 0.8 | 0.7 | 9 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.